We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Cooperativity Between Myeloid Lineages Promotes Langerhans Cell Histiocytosis Pathology

By LabMedica International staff writers
Posted on 04 Jan 2023

Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia seen in children and adults who present with lesions composed of pathologic variants of myeloid cells that share certain phenotypic features with Langerhans cells normally found in the epidermis. More...

LCH is a potentially fatal neoplasm characterized by the aberrant differentiation of mononuclear phagocytes, driven by mitogen-activated protein kinase (MAPK) pathway activation. LCH cells may trigger destructive pathology yet remain in a precarious state finely balanced between apoptosis and survival, supported by a unique inflammatory milieu.

An International team of Clinical Pathologists led by the group at the Karolinska Institutet (Stockholm, Sweden) used single-cell RNA-seq and protein analysis to dissect LCH lesions, assessing LCH cell heterogeneity and comparing LCH cells with normal mononuclear phagocytes within lesions. They used cryopreserved lesional cell suspension analysis from recruited pediatric patients with LCH. Cell suspensions from lesions of pediatric patients with LCH were index-sorted on a FACSAria III (BD Biosciences, San Diego, CA, USA).

Among the many methods used by the team were: index sorting and preprocessing, quality assessment and analysis of Smart-seq2 single-cell transcriptome data; trajectory inference and single-cell entropy analysis; gene regulatory network, cell-cell communication, and RNA velocity analysis; analysis of single-cell skin data from database DISCO integrated with LCH data; culture systems, preparation of skin and gut samples, and staining; and immunofluorescent analysis of tissue sections was performed using the MACSima Imaging Platform (Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany), which enables fully automated immunofluorescent labeling and imaging of individual biological samples.

The investigators reported that they had found LCH discriminatory signatures pointing to senescence and escape from tumor immune surveillance. They also uncovered two major lineages of LCH with DC2- and DC3/monocyte-like phenotypes and validated them in multiple pathological tissue sites by high-content imaging. Receptor-ligand analyses and lineage tracing in vitro revealed Notch-dependent cooperativity between DC2 and DC3/monocyte lineages during expression of the pathognomonic LCH program. Signaling mediated by the Notch pathway enables these two cellular lineages to cooperatively form LCH lesions.

The authors concluded that their data suggest a dual origin model of LCH cells, linked by Notch-mediated cooperativity, and provide several new insights into the development of LCH lesions and their potential vulnerabilities to new therapeutic approaches. A single-cell dissection of neoplastic histiocytes and their microenvironment allows clear differentiation of functions between lineages, illustrating the potential for a tissue program to be initiated and generated by cross-talk between more than one immune cell type. The study was published on December 16, 2022 in the journal Science Immunology.

Related Links:
Karolinska Institutet
BD Biosciences
Miltenyi Biotec


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
An overview of the study and findings: A) Several brain-derived EVPs cross the blood brain barrier and reach circulation. B) Different EVPs enrich different RNA cargo B) The EVP-RNA is impacted, upregulated (green) or downregulated (red) in AD (Gonzalez-Kozlova, E., et al., Nature Communications (2026). doi.org/10.1038/s41467-026-74541-8)

RNA Blood Test May Enable Earlier Alzheimer’s Disease Diagnosis

Alzheimer’s disease affects an estimated 55 million people worldwide and remains difficult to diagnose at an early stage. Diagnostic workups can be complicated by symptom overlap with other conditions,... Read more

Microbiology

view channel
Image: Multidrug-resistant Klebsiella pneumoniae is a growing community health concern, causing recurrent UTIs in older adults and complicating first-line antibiotic treatment (Image Credit: Adobe Stock)

Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella

Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.